Shots:
- Alloy Therapeutics has entered into a collaboration & license agreement with Biogen to advance antisense therapeutics against multiple undisclosed targets using Alloy’s AntiClastic ASO Platform
- As per the deal, Alloy will receive an upfront payment, along with additional milestone payments & tiered royalties on any products resulting from the collaboration
- The AntiClastic ASO platform creates novel oligonucleotide formats, available via partnerships with Alloy’s Genetic Medicines division, to address potency & therapeutic index challenges limiting antisense drugs
Ref: Businesswire | Image: Biogen & Alloy | Press Release
Related News: Biogen to Acquire Apellis Pharmaceuticals for ~$5.6B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
